Press Releases

 
Press Releases
  Date Title and Summary View
Feb 3, 2016
REDWOOD CITY, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on February 1, 2016, the compensation committee of the company's board of directors granted 10 new employees options to purchase an aggregate of 17,800 shares of the company's common stock with a per share exercis...
Feb 2, 2016
REDWOOD CITY, Calif., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016 at 1:00 p.m. ET. To access the live webcasts and subsequent archived recordings of these presentations...
Jan 25, 2016
Relypsa reports results from Phase 1 in vivo studies in healthy volunteers evaluating potential drug-drug interactions between Veltassa and 12 drugs administered either at the same time or three hours apartThe 12 drugs were selected based on results of previously announced in vitro tests, in which Veltassa had demonstrated binding with 14 of 28 dru...
Jan 19, 2016
REDWOOD CITY, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on January 15, 2016, the compensation committee of the company's board of directors granted 12 new employees options to purchase an aggregate of 39,000 shares of the company's common stock with a per share exercis...
Jan 5, 2016
REDWOOD CITY, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on January 4, 2016, the compensation committee of the company's board of directors granted 10 new employees options to purchase an aggregate of 34,600 shares of the company's common stock with a per share exercise...
Dec 21, 2015
Veltassa is the first FDA-approved medicine for hyperkalemia in more than 50 years Veltassa will be distributed to patients via two nationally-recognized specialty pharmaciesHospitals will receive Veltassa through a network of authorized specialty distributorsRelypsa's ...
Dec 17, 2015
REDWOOD CITY, Calif., Dec. 17, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on December 15, 2015, the compensation committee of the company's board of directors granted 41 new employees options to purchase an aggregate of 89,100 shares of the company's common stock with ...
Dec 7, 2015
REDWOOD CITY, Calif., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on December 1, 2015, the compensation committee of the company's board of directors granted 65 new employees options to purchase an aggregate of 129,600 shares of the company's common stock with a per share e...
Dec 1, 2015
REDWOOD CITY, Calif., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Oppenheimer 26th Annual Healthcare Conference on December 8, 2015 at 2:10 p.m. ET. To access the live webcasts and subsequent archived recordings of these presentat...
Nov 19, 2015
REDWOOD CITY, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on November 16, 2015, the compensation committee of the company's board of directors granted three new employees options to purchase an aggregate of 6,250 shares of the company's common stock w...
Page:
1
... NextLast
= add release to Briefcase